Practical management of lupus nephritis in pregnancy and the puerperium

Expert Review of Clinical Pharmacology

Volumn 3, Issue 6, 2010, Pages 777-784

  Karim, M Yousuf ^a,b   Dcruz, David P ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b FRIMLEY PARK HOSPITAL   (United Kingdom)

Author keywords

anti dsDNA antibodies; antiphospholipid; glomerulonephritis; miscarriage; pre eclampsia; renal; systemic lupus erythematosus; teratogenic

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; CELL NUCLEUS ANTIGEN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOUBLE STRANDED DNA ANTIBODY; HYDROCORTISONE; HYDROXYCHLOROQUINE; LABETALOL; LOW MOLECULAR WEIGHT HEPARIN; METHOTREXATE; METHYLDOPA; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHOSPHOLIPID ANTIBODY; PREDNISOLONE; RITUXIMAB;

ANTIPHOSPHOLIPID SYNDROME; BLOOD PRESSURE REGULATION; BREAST MILK; CHROMOSOME ABERRATION; CLINICAL ASSESSMENT; CONGENITAL MALFORMATION; CREATININE BLOOD LEVEL; CYTOPENIA; DISEASE EXACERBATION; DRUG CONTRAINDICATION; DRUG MILK LEVEL; DRUG SAFETY; FETUS ECHOGRAPHY; FETUS MONITORING; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNE STATUS; KIDNEY BIOPSY; KIDNEY FUNCTION; LABORATORY TEST; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE DEPLETION; NEWBORN DEATH; PATIENT INFORMATION; PATIENT MONITORING; PREGNANCY; PREGNANCY OUTCOME; PROTEIN URINE LEVEL; PUERPERIUM; REVIEW; SECOND TRIMESTER PREGNANCY; SIDE EFFECT; SPONTANEOUS ABORTION; STILLBIRTH; TERATOGENICITY; THIRD TRIMESTER PREGNANCY; URINE SEDIMENT;

EID: 78649383181     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/ecp.10.55     Document Type: Review

References (44)

1. Clark CA, Spitzer KA, Laskin CA. Decrease in pregnancy loss rates in patients with systemic lupus erythematosus over a 40-year period. J. Rheumatol. 32(9), 1709-1712 (2005).
2. Tuthill JI, Khamashta MA. Management of antiphospholipid syndrome. J. Autoimmun. 33(2), 92-98 (2009).
3. Mackillop LH, Germain SJ, Nelson-Piercy C. Systemic lupus erythematosus. Br. Med. J. 335(7626), 933-936 (2007).
4. Day CJ, Lipkin GW, Savage CO. Lupus nephritis and pregnancy in the 21st century. Nephrol. Dial. Transplant. 24(2), 344-347 (2009).
5. Williams D, Davison J. Chronic kidney disease in pregnancy. Br. Med. J. 336(7637), 211-215 (2008).
6. Cunningham FG, Cox SM, Harstad TW, Mason RA, Pritchard JA. Chronic renal disease and pregnancy outcome. Am. J. Obstet. Gynecol. 163(2), 453-459 (1990).
7. Smith MC, Moran P, Ward MK, Davison JM. Assessment of glomerular fltration rate during pregnancy using the MDRD formula. BJOG 115(1), 109-112 (2008).
8. Clowse ME, Jamison M, Myers E, James AH. A national study of the complications of lupus in pregnancy. Am. J. Obstet. Gynecol. 199(2), 127.e1-6 (2008).
9. Gladman DD, Tandon A, Ibañez D, Urowitz MB. The effect of lupus nephritis on pregnancy outcome and fetal and maternal complications. J. Rheumatol 37(4), 754-758 (2010).
10. Ruiz-Irastorza G, Lima F, Alves J et al Increased rate of lupus fare during pregnancy and the puerperium; a prospective study of 78 pregnancies. Rheumatology 35(2), 133-138 (1996).
11. Petri M, Howard D, Repke J. Frequency of lupus fare in pregnancy. The Hopkins Lupus Pregnancy Center experience. Arthritis Rheum. 34(12), 1538-1545 (1991).
12. Lockshin MD, Reinitz E, Druzin ML, Murrman M, Estes D. Lupus pregnancy: casecontrol prospective study demonstrating absence of lupus exacerbation during or after pregnancy. Am. J. Med. 77(5), 893-898, (1984).
13. Moroni G, Quaglini S, Banf G et al. Pregnancy in lupus nephritis. Am. J. Kidney Dis. 40(4), 713-720 (2002).
14. Imbasciati E, Tincani A, Gregorini G et al Pregnancy in women with pre-existing lupus nephritis: predictors of fetal and maternal outcome. Nephrol. Dial Transplant. 24(2), 519-525 (2009).
15. Wagner SJ, Craici I, Reed D et al. Maternal and foetal outcomes in pregnant patients with active lupus nephritis. Lupus 18(4), 342-347 (2009).
16. Huong DL, Wechsler B, Vauthier-Brouzes D, Beaufls H, Lefebvre G, Piette JC. Pregnancy in past or present lupus nephritis: a study of 32 pregnancies from a single centre. Ann. Rheum. Dis. 60(6), 599-604 (2001).
17. Carmona F, Font J, Moga I et al. Class III-IV proliferative lupus nephritis and pregnancy: a study of 42 cases. Am. J. Reprod. Immunol. 53(4), 182-188 (2005).
18. Germain S, Nelson-Piercy C. Lupus nephritis and renal disease in pregnancy. Lupus 15(3), 148-155 (2006).
19. Nelson-Piercy C. Renal disease. In: Handbook of Obstetric Medicine (3rd Ed.) Informa Healthcare, London, UK, 180-198 (2006).
20. Alba P, Bento L, Cuadrado MJ et al Anti-dsDNA, anti-Sm antibodies and the lupus anticoagulant: signifcant factors associated with lupus nephritis. Ann. Rheum. Dis. 62(6), 556-560 (2003).
21. Patel M, Clarke AM, Bruce IN, Symmons DP. The prevalence and incidence of biopsy-proven lupus nephritis in the UK: evidence of an ethnic gradient. Arthritis Rheum. 54(9), 2963-2969 (2006).
22. Marto N, Bertolaccini ML, Calabuig E, et al. Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann. Rheum. Dis. 64(3), 444-448 (2005).
23. Cortés-Hernández J, Ordi-Ros J, Labrador M et al. Antihistone and anti-double-stranded deoxyribonucleic acid antibodies are associated with renal disease in systemic lupus erythematosus. Am. J. Med. 116(3), 165-173 (2004).
24. Karim MY, Yong PF, D'Cruz DP. Clinical importance of autoantibodies in lupus nephritis. Expert Rev. Clin. Immunol. 3(6), 937-947 (2007).
25. Mosca M, Strigini F, Doria A et al Anti-C1q antibodies in pregnant patients with systemic lupus erythematosus. Clin. Exp. Rheumatol. 25(3), 449-452 (2007).
26. Hayslett JP. The effect of systemic lupus erythematosus on pregnancy and pregnancy outcome. Am. J. Reprod. Immunol. 28(3-4), 199-204 (1992).
27. Tench CM, Isenberg DA. The variation in anti-ENA characteristics between different ethnic populations with systemic lupus erythematosus over a 10-year period. Lupus 9(5), 374-376 (2000)
28. Østensen M, Khamashta M, Lockshin M et al. Anti-infammatory and immunosuppressive drugs and reproduction. Arthritis Res. Ther. 8(3), 209 (2006).
29. Kong NC. Pregnancy of a lupus patient-a challenge to the nephrologist. Nephrol. Dial. Transplant. 21(2), 268-272 (2006).
30. Cooper WO, Hernandez-Diaz S, Arbogast G et al. Major congenital malformations after frst-trim ester exposure to ACE inhibitors. N. Engl. J. Med. 354(23), 2443-2451 (2006).
31. Von Dadelszen P, Ornstein MP, Bull SB, Logan AG, Koren G, Magee LA. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. Lancet 355(9198), 87-92 (2000).
32. Ostensen M, Lockshin M, Doria A et al Update on safety during pregnancy of biological agents and some immunosuppressive antirheumatic drugs. Rheumatology. 47(Suppl. 3), iii28-iii31 (2008).
33. Ojeda-Uribe M, Gilliot C, Jung G, et al. Administration of rituximab during the frst trimester of pregnancy without consequences for the newborn. J. Perinatol. 26(4), 252-255 (2006).
34. Klink DT, van Elburg RM, Schreurs MW, van Well GT. Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development. Clin. Dev. Immunol. 2008, 271363 (2008).
35. Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst. Rev. 18(2), CD004659 (2007).
36. Gauer R, Atlas M, Hill J. Clinical inquiries. Does low-dose aspirin reduce preeclampsia and other maternal-fetal complications? J. Fam. Pract. 57(1), 54-56 (2008).
37. Bujold E, Roberge S, Lacasse Y et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet. Gynecol. 116(2, Part 1), 402-414 (2010).
38. Le Thi Huong D, Wechsler B, Vauthier-Brouzes D et al. The second trimester Doppler ultrasound examination is the best predictor of late pregnancy outcome in systemic lupus erythematosus and/or the anti/phospholipid syndrome. Rheumatology 45(3), 332-338 (2006).
39. Friedman DM, Kim MY, Copel JA et al. Utility of cardiac monitoring in fetuses at risk for congenital heart block: the PR Interval and Dexamethasone Evaluation (PRIDE) prospective study. Circulation 117(4), 485-493 (2008).
40. Cote AM, Brown MA, Lam E et al. Diagnostic accuracy of urinary spot protein:creatinine ratio for proteinuria in hypertensive pregnant women: systematic review. Br. Med. J. 336 (7651), 1003-1006 (2008).
41. Salesi M, Karimifar M, Farajzadegan Z et al. The protein-creatinine ratio in spot morning urine samples and 24-h urinary protein excretion in patients with systemic lupus erythematosus. Rheumatol. Int. 29(5), 503-507 (2009).
42. Hebert LA, Birmingham DJ, Shidham G, et al. Random spot urine protein/creatinine ratio is unreliable for estimating 24-hour proteinuria in individual systemic lupus erythematosus nephritis patients. Nephron. Clin. Pract. 113(3), c177-c182 (2009).
43. Buhimschi CS, Magloire L, Funai E et al. Fractional excretion of angiogenic factors in women with severe preeclampsia. Obstet. Gynecol. 107(5), 1103-1113 (2006).
44. Sunderji S, Gaziano E, Wothe D et al. Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study. Am. J. Obstet. Gynecol. 202(1), 40.e1-7 (2010).